ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011
Understanding surgical decision making in early hepatocellular carcinoma.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2012Pooled it
- Tumor-Targeted FABP5/STING Cascade Promote Radiofrequency Ablation Induced Ferroptosis and Intratumoral Immune Rewiring in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Impact of patient sex on selection for abdominal aortic aneurysm repair: a discrete choice experiment.BMJ open · 2025Article
- Scoping review of values elicitation tools for treatment decisions in hepatocellular carcinoma.BMC gastroenterology · 2024Article
- Balancing choice and socioeconomic realities: analyzing behavioral and economic factors in social oocyte cryopreservation decisions.Frontiers in endocrinology · 2024Article
- Treatment Disparities Partially Mediate Socioeconomic- and Race/Ethnicity-Based Survival Disparities in Stage I-II Hepatocellular Carcinoma.Annals of surgical oncology · 2023Article
- Identification of Relevant Attributes for Liver Cancer Therapies (IRALCT): a maximum-difference-scaling analysis.Scientific reports · 2022Review
- Clinical Decision-Making for Heart Failure in Kosovo: A Conjoint Analysis.International journal of environmental research and public health · 2022Article
- Clinical Decision-Making for Appendectomy in Kosovo: A Conjoint Analysis.International journal of environmental research and public health · 2022Article
- Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2022Article
- And When I Die: Theory of Planned Behavior as Applied to Sperm Cryopreservation.Healthcare (Basel, Switzerland) · 2021Article
- Understanding surgical decision-making in older adults with differentiated thyroid cancer: A discrete choice experiment.Surgery · 2021Article
- Impact of Surveillance in Chronic Hepatitis B Patients on Long-Term Outcomes After Curative Liver Resection for Hepatocellular Carcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Article
- Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan.PloS one · 2020Article
- Identification of Actual 10-Year Survival After Hepatectomy of HBV-Related Hepatocellular Carcinoma: a Multicenter Study.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2019Article
- Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size.Frontiers in oncology · 2019Article
- Assessing resectability of colorectal liver metastases: How do different subspecialties interpret the same data?Canadian journal of surgery. Journal canadien de chirurgie · 2018Article
- Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: from a transplant oncology viewpoint.Hepatobiliary surgery and nutrition · 2018Article
- Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.Surgery today · 2017Review
- Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.Patient preference and adherence · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThe choice between liver transplantation (LT), liver resection (LR), and radiofrequency ablation (RFA) as initial therapy for early hepatocellular carcinoma (HCC) is controversial, yet little is known about how surgeons choose therapy for individual patients. We sought to quantify the impact of both clinical factors and surgeon specialty on surgical decision making in early HCC by using conjoint analysis.
methodsSurgeons with an interest in liver surgery were invited to complete a Web-based survey including 10 case scenarios. Choice of therapy was then analyzed by using regression models that included both clinical factors and surgeon specialty (non-LT v LT).
resultsWhen assessing early HCC occurrences, non-LT surgeons (50% LR; 41% LT; 9% RFA) made significantly different recommendations compared with LT surgeons (63% LT; 31% LR; 6% RFA; P < .001). Clinical factors, including tumor number and size, type of resection required, and platelet count, had significant effects on the choice between LR, LT, and RFA. After adjusting for clinical factors, non-LT surgeons remained more likely than LT surgeons to choose LR compared with LT (relative risk ratio [RRR], 2.67). When the weight of each clinical factor was allowed to vary by surgeon specialty, the residual independent effect of surgeon specialty on the decision between LR and LT was negligible (RRR, 0.93).
conclusionThe impact of surgeon specialty on choice of therapy for early HCC is stronger than that of some clinical factors. However, the influence of surgeon specialty does not merely reflect an across-the-board preference for one therapy over another. Rather, certain clinical factors are weighed differently by surgeons in different specialties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.